scholarly journals Long-term clinical effectiveness of lithium maintenance treatment in types I and II bipolar disorders

2001 ◽  
Vol 178 (S41) ◽  
pp. s184-s190 ◽  
Author(s):  
Leonardo Tondo ◽  
Ross J. Baldessarini ◽  
Gianfranco Floris
Keyword(s):  
Substance Use ◽  
Substance Use Disorder ◽  
Lithium Treatment ◽  
Bipolar Disorders ◽  
Clinical Effectiveness ◽  
Type I ◽  
Rapid Cycling ◽  
Single Episode ◽  
Episode Frequency

BackgroundThe effectiveness of lithium is being questioned increasingly and requires clarification.AimsTo assess the effectiveness of lithium treatment in depression and mania, syndromal types I and II, with predominantly mixed or psychotic episodes or rapid cycling, during treatment resumed following discontinuation, and across three decades.MethodThe longitudinal course of 360 patients with bipolar disorder compliant with lithium treatment for at least 1 year and without comorbidity for substance use disorder was reviewed.ResultsRisk of single-episode recurrences, a common index of treatment failure, was similar to that in other reports. Both episode frequency and ‘time ill’ improved more in type II than type I cases. Reduced morbidity during treatment was similar in patients with mixed or psychotic episodes, or rapid cycling, and in less complex cases. Retreatment yielded minor decrements in response, and there was no tendency for lesser responses in more recent years.ConclusionsBased on overall affective morbidity, long-term lithium treatment in compliant patients without comorbid substance use disorder, though imperfect, remains effective, even in subgroups of supposedly poor prognosis.

Predicting attrition in long-term residential substance use disorder treatment: A modifiable risk factors perspective.

2020 ◽  
Vol 17 (4) ◽  
pp. 472-482
Author(s):  
Danielle E. Baker ◽  
Keith A. Edmonds ◽  
Maegan L. Calvert ◽  
Sarah M. Sanders ◽  
Ana J. Bridges ◽  
...  
Keyword(s):  
Risk Factors ◽  
Substance Use ◽  
Substance Use Disorder ◽  
Modifiable Risk Factors ◽  
Substance Use Disorder Treatment ◽  
Disorder Treatment

scholarly journals Recovery-informed Theory: Situating the Subjective in the Science of Substance Use Disorder Recovery

2019 ◽  
Vol 1 (3) ◽  
pp. 1-15 ◽  
Author(s):  
Austin M Brown ◽  
Robert D Ashford
Keyword(s):  
Substance Use ◽  
Substance Use Disorders ◽  
Substance Use Disorder ◽  
Systems Of Care ◽  
Grand Theory ◽  
Recovery Strategies ◽  
Recovery Capital ◽  
New Ideas

As recovery from substance use disorder becomes more than a mere quantifiable outcome, there exists a need to discuss and propose the underlying theoretical constructs that ultimately describe and identify the science of recovery. In this abstract undertaking, we propose an initial formulation of a grand theory of recovery science, built upon the seminal theories of recovery capital, recovery-oriented systems of care, and socioecological theory. This grand theory - labeled recovery-informed theory (RIT) - states that successful long-term recovery is self-evident and is a fundamentally emancipatory set of processes. This paper will discuss, analyze, and explore this theory as it is situated within the larger substance use, misuse, and disorder contexts. The uses, implications, and benefits of RIT as an organizing point of inquiry for recovery science are also discussed. By promoting the role of subjective recovery experience in the formulation of the study of recovery, it may be possible to summon new ideas, metrics, and strategies that can directly address substance use disorders in society. Adopting a recovery-informed understanding as follows from this grand theory may allow individual recovery and wellness trajectories to be explored, adapted, and modified to exemplify person-centered and individualized recovery strategies.

scholarly journals Memantine in the management of affective recurrences of bipolar disorders after the discontinuation of long-term lithium treatment: three case histories

2013 ◽  
Vol 4 (1) ◽  
pp. 53-55 ◽  
Author(s):  
Giulia Serra ◽  
Lavinia De Chiara ◽  
Giovanni Manfredi ◽  
Alexia E. Koukopoulos ◽  
Gabriele Sani ◽  
...  
Keyword(s):  
Lithium Treatment ◽  
Bipolar Disorders ◽  
Case Histories

scholarly journals Treatments for Adolescents With Comorbid ADHD and Substance Use Disorder: A Systematic Review

2015 ◽  
Vol 24 (9) ◽  
pp. 1215-1226 ◽  
Author(s):  
Michelle J. Zaso ◽  
Aesoon Park ◽  
Kevin M. Antshel
Keyword(s):  
Systematic Review ◽  
Substance Use ◽  
Substance Use Disorder ◽  
Pharmacological Intervention ◽  
Psychotherapeutic Interventions ◽  
Effective Interventions ◽  
Potential Efficacy ◽  
Treatment Gains ◽  
Comorbid Adhd

Objective: Comorbid ADHD and substance use disorder (SUD) presents frequently in adolescence, a developmental period that may promote the emergence of substance misuse among individuals with ADHD. Comorbid ADHD and SUD in adolescence results in significant and unique treatment challenges, necessitating examination into effective interventions. Method: This systematic review examined existing research into the treatment of comorbid adolescent ADHD and SUD. Results: Findings from a small number of pharmacological intervention studies suggest potential efficacy of extended-release stimulant and nonstimulant medications. Efficacy of psychotherapeutic interventions has not been systematically examined. Conclusion: Current research on treatments for comorbid ADHD and SUD in adolescence is limited. Future placebo-controlled clinical trials using large samples are needed to examine the efficacy of psychotherapeutic interventions, the heightened risk of prescription stimulant misuse, and the long-term maintenance of treatment gains in this population. Clinical guidelines for the treatment of comorbid ADHD and SUD are discussed.

scholarly journals Does the efficacy of asenapine in bipolar disorder increase in the presence of comorbidity with a substance use disorder? A naturalistic study

2016 ◽  
Vol 7 (2) ◽  
pp. 67-77 ◽  
Author(s):  
Sergio De Filippis ◽  
Ilaria Cuomo ◽  
Georgios D. Kotzalidis ◽  
Daniela Pucci ◽  
Pietro Zingaretti ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Substance Use ◽  
Substance Use Disorder ◽  
Repeated Measures ◽  
Rating Scale ◽  
Type I ◽  
Open Label ◽  
Young Mania ◽  
Psychiatric Rating ◽  
Psychiatric Rating Scale

Background: Asenapine is a second-generation antipsychotic approved in Europe for treating moderate-to-severe manic episodes in adults affected by type I bipolar disorder (BD-I). We aimed to compare its efficacy in psychiatric inpatients with BD-I, with or without substance use disorder (SUD). Methods: We administered flexible asenapine doses ranging from 5–20 mg/day to 119 voluntarily hospitalized patients with Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) BD-I diagnosis, with or without SUD. Patients were assessed with clinician-rated questionnaires [i.e. Brief Psychiatric Rating Scale (BPRS), Young Mania Rating Scale (YMRS), Hamilton Depression Rating Scale (HDRS), Hamilton Anxiety Rating Scale (HARS), and Global Assessment of Functioning (GAF)]. Assessments were carried out at baseline (T0, prior to treatment), and 3 (T1), 7 (T2), 15 (T3), and 30 days (T4) after starting treatment for all clinical scales and at T0 and T4 for the GAF. Results: Patients improved on all scales ( p < 0.001) across all timepoints, as shown both by paired-sample comparisons and by applying a repeated-measures, generalized linear model (GLM). Patients without comorbid SUD showed greater reductions in BPRS scores at T2 and T3, greater reduction in YMRS scores at T3, and lower HARS scores at all timepoints. HDRS scores did not differ between the two groups at any timepoint. However, the reduction in HARS scores in the comorbid group was stronger than in the BD-I only group, albeit not significantly. Side effects were few and mild-to-moderate. Conclusions: The open-label design and the relatively short observation period may expose to both type I and type II statistical errors (false positive and false negatives). Asenapine showed effectiveness and safety in hospitalized BD-I patients. Its effect was stronger in patients without comorbid SUD.

scholarly journals Substance Use Disorder in Early Midlife: A National Prospective Study on Health and Well-Being Correlates and Long-Term Predictors

2015 ◽  
Vol 9s1 ◽  
pp. SART.S31437 ◽  
Author(s):  
John E. Schulenberg ◽  
Megan E. Patrick ◽  
Deborah D. Kloska ◽  
Julie Maslowsky ◽  
Jennifer L. Maggs ◽  
...  
Keyword(s):  
Substance Use ◽  
Substance Use Disorder ◽  
Well Being ◽  
Cannabis Use ◽  
Adult Health ◽  
Senior Year ◽  
Cognitive Difficulties ◽  
Monitoring The Future ◽  
Health And Well Being

This study used national multicohort panel data from the Monitoring the Future study ( N = 25,536 from senior year classes 1977–1997 followed up to the age of 35 years in 1994–2014) to examine how early midlife (age 35 years) alcohol use disorder (AUD) and cannabis use disorder (CUD) are associated with adolescent and adult sociodemographics and health and well-being risk factors. Survey items adapted from DSM-5 diagnostic criteria were used to identify individuals who (a) showed symptoms consistent with criteria for AUD or CUD at age 35 years, (b) used the substance without qualifying for a disorder (nondisordered users), and (c) abstained from using alcohol or marijuana during the past five years. At age 35 years, the estimated prevalence of past five-year AUD was 28.0%, and that of CUD was 6.1%. Multinomial logistic regressions were used to identify variations in the relative risk of disorder symptoms as a function of sociodemographic characteristics, age 18 educational and social indices and substance use, and age 35 health and satisfaction indices and substance use. In the full models, age 18 binge drinking and marijuana use were found to be among the strongest predictors of age 35 AUD and CUD, respectively. Among age 35 health and well-being indicators, lower overall health, more frequent cognitive difficulties, and lower satisfaction with spouse/partner were consistently associated with greater risks of AUD and CUD. Some evidence was found for a J-shaped association between age 35 AUD or CUD status and health and well-being indices, such that nondisordered users were sometimes better off than both abstainers and those experiencing disorder. Finally, nondisordered cannabis use, but not CUD, was found to be more common in more recent cohorts. Implications are discussed regarding the importance of placing early midlife substance use disorder within the context of both adolescent substance use and adult health and well-being.

scholarly journals Differential interactions between comorbid anxiety disorders and substance use disorder in rapid cycling bipolar I or II disorder

2008 ◽  
Vol 110 (1-2) ◽  
pp. 167-173 ◽  
Author(s):  
Keming Gao ◽  
Bryan K. Tolliver ◽  
David E. Kemp ◽  
Marcia L. Verduin ◽  
Stephen J. Ganocy ◽  
...  
Keyword(s):  
Substance Use ◽  
Anxiety Disorders ◽  
Substance Use Disorder ◽  
Rapid Cycling ◽  
Comorbid Anxiety

Mood Stabilizers in the Treatment of Substance Use Disorders

CNS Spectrums ◽  
2010 ◽  
Vol 15 (2) ◽  
pp. 95-109 ◽  
Author(s):  
Icro Maremmani ◽  
Matteo Pacini ◽  
Francesco Lamanna ◽  
Pier Paolo Pani ◽  
Giulio Perugi ◽  
...  
Keyword(s):  
Substance Use ◽  
Dual Diagnosis ◽  
Substance Abusers ◽  
Bipolar Disorders ◽  
Preliminary Evidence ◽  
Mood Stabilizers ◽  
Bipolar Spectrum ◽  
Bipolar Spectrum Disorders ◽  
Spectrum Disorders

ABSTRACTIndividuals suffering from drug addiction may also manifest features of bipolar spectrum disorders. Hyperthymic and cyclothymic temperaments may render individuals vulnerable to later development of substance abuse. Bipolar disorders themselves may be altered or precipitated by substance use, most notably by stimulants (amphetamines), alcohol, and cannabinoids.The clinical usefulness of mood stabilizers, particularly antiepileptics, has been established as safe and effective in substance abusers with and without comorbid mood disorders. Most studies on this issue have been of short duration and focused on the resolution of a currently manifest period of illness. Few studies have been conducted on the usefulness of these drugs on the long-term longitudinal course of these diseases, such as frequently encountered recurrent relapses into states of agitation, impulsivity, and/or dissatisfaction. As opposed to the clinical experience with traditional antidepressants and neuroleptics, antiepileptics do not induce counter-polar states (depressed patients abruptly turning manic or hypomanic; nor patients currently hypomanic or manic turning abruptly depressed). Many clinicians consider antiepileptic mood stabilizers to be the preferred category of medications for the treatment of such patients. Valproate appears to be a potentially fruitful medication to study in these dual diagnosis patients due to preliminary evidence demonstrating its anticraving efficacy.

scholarly journals Predicting substance use disorder using long-term attention deficit hyperactivity disorder medication records in Truven

2019 ◽  
Vol 26 (2) ◽  
pp. 787-802 ◽  
Author(s):  
Sajjad Fouladvand ◽  
Emily R Hankosky ◽  
Heather Bush ◽  
Jin Chen ◽  
Linda P Dwoskin ◽  
...  
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
Substance Use ◽  
Substance Use Disorder ◽  
Attention Deficit ◽  
Health Consequences ◽  
Hyperactivity Disorder ◽  
Long Term Impact

About 20% of individuals with attention deficit hyperactivity disorder are first diagnosed during adolescence. While preclinical experiments suggest that adolescent-onset exposure to attention deficit hyperactivity disorder medication is an important factor in the development of substance use disorder phenotypes in adulthood, the long-term impact of attention deficit hyperactivity disorder medication initiated during adolescence has been largely unexplored in humans. Our analysis of 11,624 adolescent enrollees with attention deficit hyperactivity disorder in the Truven database indicates that temporal medication features, rather than stationary features, are the most important factors on the health consequences related to substance use disorder and attention deficit hyperactivity disorder medication initiation during adolescence.

Try to Remember: Interplay between Memory and Substance Use Disorder

2018 ◽  
Vol 20 (2) ◽  
pp. 158-165 ◽  
Author(s):  
Rashidi Mohamed Pakri Mohamed ◽  
Jaya Kumar ◽  
Ernie Yap ◽  
Isa Naina Mohamed ◽  
Hatta Sidi ◽  
...  
Keyword(s):  
Substance Use ◽  
Substance Use Disorder ◽  
Pharmacological Intervention ◽  
Long Term Memory ◽  
Potential Candidate ◽  
Learning Disorder ◽  
Inhibitory Peptide ◽  
Term Memory ◽  
Biochemical Mechanisms

Memories associated with substance use disorders, or substance-associated cues increase the likelihood of craving and relapse during abstinence. There is a growing consensus that manipulation of synaptic plasticity may reduce the strength of substance abuse-related memories. On the biological front, there are new insights that suggest memories associated with substance use disorder may follow unique neurobiological pathways that render them more accessible to pharmacological intervention. In parallel to this, research in neurochemistry has identified several potential candidate molecules that could influence the formation and maintenance of long-term memory. Drugs that target these molecules (blebbistatin, isradipine and zeta inhibitory peptide) have shown promise at the preclinical stage. In this review, we shall provide an overview of the evolving understanding on the biochemical mechanisms involved in memory formation and expound on the premise that substance use disorder is a learning disorder.

Sign in / Sign up

Export Citation Format

Share Document